Goddard Glenn 4/A
4/A · Intellia Therapeutics, Inc. · Filed Mar 4, 2022
Insider Transaction Report
Form 4/AAmended
Goddard Glenn
EVP, Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-03-01+18,600→ 18,600 totalExercise: $79.85Exp: 2032-02-28→ Common Stock (18,600 underlying)
Footnotes (2)
- [F1]The original Form 4 incorrectly reported the number of options granted as 12,720.
- [F2]This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.